AnaptysBio (NASDAQ:ANAB) Given “Outperform” Rating at Wedbush

Wedbush reissued their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research report sent to investors on Monday,RTT News reports. They currently have a $40.00 price target on the biotechnology company’s stock.

A number of other brokerages also recently weighed in on ANAB. Guggenheim cut their price target on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. JPMorgan Chase & Co. cut their price target on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Truist Financial cut their price target on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. UBS Group boosted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Finally, BTIG Research downgraded shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, AnaptysBio currently has a consensus rating of “Moderate Buy” and an average price target of $41.45.

AnaptysBio Stock Down 7.1 %

Shares of NASDAQ ANAB opened at $16.66 on Monday. The company has a market capitalization of $506.96 million and a PE ratio of -2.74. The stock’s 50 day moving average price is $17.38 and its 200-day moving average price is $27.01. AnaptysBio has a twelve month low of $12.51 and a twelve month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. The firm had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, research analysts expect that AnaptysBio will post -6.08 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In other news, Director Ecor1 Capital, Llc purchased 6,646 shares of the stock in a transaction dated Thursday, January 2nd. The shares were purchased at an average cost of $12.95 per share, with a total value of $86,065.70. Following the completion of the acquisition, the director now owns 7,880,094 shares in the company, valued at $102,047,217.30. This represents a 0.08 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 33.70% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Institutional investors and hedge funds have recently modified their holdings of the company. The Manufacturers Life Insurance Company increased its position in shares of AnaptysBio by 49.8% in the second quarter. The Manufacturers Life Insurance Company now owns 25,312 shares of the biotechnology company’s stock worth $634,000 after purchasing an additional 8,418 shares during the last quarter. Algert Global LLC increased its position in shares of AnaptysBio by 11.8% in the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after purchasing an additional 1,078 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of AnaptysBio in the third quarter worth approximately $405,000. nVerses Capital LLC increased its position in shares of AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after purchasing an additional 168,813 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.